240 related articles for article (PubMed ID: 18420784)
1. Metabolism and disposition of dasatinib after oral administration to humans.
Christopher LJ; Cui D; Wu C; Luo R; Manning JA; Bonacorsi SJ; Lago M; Allentoff A; Lee FY; McCann B; Galbraith S; Reitberg DP; He K; Barros A; Blackwood-Chirchir A; Humphreys WG; Iyer RA
Drug Metab Dispos; 2008 Jul; 36(7):1357-64. PubMed ID: 18420784
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation of [14C]dasatinib: in vitro studies in rat, monkey, and human and disposition after administration to rats and monkeys.
Christopher LJ; Cui D; Li W; Barros A; Arora VK; Zhang H; Wang L; Zhang D; Manning JA; He K; Fletcher AM; Ogan M; Lago M; Bonacorsi SJ; Humphreys WG; Iyer RA
Drug Metab Dispos; 2008 Jul; 36(7):1341-56. PubMed ID: 18420785
[TBL] [Abstract][Full Text] [Related]
3. Identification of the human enzymes involved in the oxidative metabolism of dasatinib: an effective approach for determining metabolite formation kinetics.
Wang L; Christopher LJ; Cui D; Li W; Iyer R; Humphreys WG; Zhang D
Drug Metab Dispos; 2008 Sep; 36(9):1828-39. PubMed ID: 18556438
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
5. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure.
Luo FR; Yang Z; Camuso A; Smykla R; McGlinchey K; Fager K; Flefleh C; Castaneda S; Inigo I; Kan D; Wen ML; Kramer R; Blackwood-Chirchir A; Lee FY
Clin Cancer Res; 2006 Dec; 12(23):7180-6. PubMed ID: 17145844
[TBL] [Abstract][Full Text] [Related]
6. Metabolism and disposition of imatinib mesylate in healthy volunteers.
Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
[TBL] [Abstract][Full Text] [Related]
7. Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL), a multi-targeted kinase inhibitor.
Luo FR; Barrett YC; Yang Z; Camuso A; McGlinchey K; Wen ML; Smykla R; Fager K; Wild R; Palme H; Galbraith S; Blackwood-Chirchir A; Lee FY
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1065-74. PubMed ID: 18301894
[TBL] [Abstract][Full Text] [Related]
8. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
Kamath AV; Wang J; Lee FY; Marathe PH
Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
[TBL] [Abstract][Full Text] [Related]
9. Dasatinib.
Korashy HM; Rahman AF; Kassem MG
Profiles Drug Subst Excip Relat Methodol; 2014; 39():205-37. PubMed ID: 24794907
[TBL] [Abstract][Full Text] [Related]
10. Once-daily dasatinib for treatment of patients with chronic myeloid leukemia.
Tyler T
Ann Pharmacother; 2009 May; 43(5):920-7. PubMed ID: 19336654
[TBL] [Abstract][Full Text] [Related]
11. Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats.
He K; Lago MW; Iyer RA; Shyu WC; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2008 Dec; 36(12):2564-70. PubMed ID: 18787054
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib: BMS 354825.
Drugs R D; 2006; 7(2):129-32. PubMed ID: 16542059
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous determination of methotrexate, dasatinib and its active metabolite N- deshydroxyethyl dasatinib in rat plasma by LC-MS/MS: method validation and application to pharmacokinetic study.
Thappali SR; Varanasi KV; Veeraraghavan S; Vakkalanka SK; Khagga M
Arzneimittelforschung; 2012 Dec; 62(12):624-30. PubMed ID: 23138519
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and disposition of [14C]BMS-690514, an ErbB/vascular endothelial growth factor receptor inhibitor, after oral administration to humans.
Christopher LJ; Hong H; Vakkalagadda BJ; Clemens PL; Su H; Roongta V; Allentoff A; Sun H; Heller K; Harbison CT; Iyer RA; Humphreys WG; Wong T; Zhang S
Drug Metab Dispos; 2010 Nov; 38(11):2049-59. PubMed ID: 20668249
[TBL] [Abstract][Full Text] [Related]
16. Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers.
Takusagawa S; van Lier JJ; Suzuki K; Nagata M; Meijer J; Krauwinkel W; Schaddelee M; Sekiguchi M; Miyashita A; Iwatsubo T; van Gelderen M; Usui T
Drug Metab Dispos; 2012 Apr; 40(4):815-24. PubMed ID: 22269146
[TBL] [Abstract][Full Text] [Related]
17. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
18. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
[TBL] [Abstract][Full Text] [Related]
19. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Takahashi N; Miura M; Niioka T; Sawada K
Cancer Chemother Pharmacol; 2012 Apr; 69(4):999-1004. PubMed ID: 22147077
[TBL] [Abstract][Full Text] [Related]
20. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate.
Brave M; Goodman V; Kaminskas E; Farrell A; Timmer W; Pope S; Harapanhalli R; Saber H; Morse D; Bullock J; Men A; Noory C; Ramchandani R; Kenna L; Booth B; Gobburu J; Jiang X; Sridhara R; Justice R; Pazdur R
Clin Cancer Res; 2008 Jan; 14(2):352-9. PubMed ID: 18223208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]